BS_A7Q8G0Y1
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 1.281208935611038
- age_years
- 10.244
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.412
- ANGIOGENESIS+0.403
- COAGULATION+0.332
- IL6_JAK_STAT3_SIGNALING+0.308
- ALLOGRAFT_REJECTION+0.291
- KRAS_SIGNALING_DN+0.285
- COMPLEMENT+0.274
- TNFA_SIGNALING_VIA_NFKB+0.274
- KRAS_SIGNALING_UP+0.262
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.223
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.702
- MYC_TARGETS_V1-0.604
- MYC_TARGETS_V2-0.588
- DNA_REPAIR-0.525
- UNFOLDED_PROTEIN_RESPONSE-0.493
- PROTEIN_SECRETION-0.434
- ADIPOGENESIS-0.409
- FATTY_ACID_METABOLISM-0.389
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.386
- MTORC1_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR661433 | GTEX | — | 0.889 |
| 2 | SRR1328035 | GTEX | — | 0.887 |
| 3 | SRR615515 | GTEX | — | 0.886 |
| 4 | SRR1488285 | GTEX | — | 0.883 |
| 5 | SRR613114 | GTEX | — | 0.881 |
| 6 | SRR1358561 | GTEX | — | 0.874 |
| 7 | SRR655590 | GTEX | — | 0.874 |
| 8 | SRR1418604 | GTEX | — | 0.868 |
| 9 | SRR1417070 | GTEX | — | 0.865 |
| 10 | SRR1335064 | GTEX | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.412 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.403 | Remibrutinib | — uncovered |
| COAGULATION | 0.332 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.308 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.291 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.285 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.274 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.274 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.262 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.223 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.204 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.175 | Inavolisib | — uncovered |
| MYOGENESIS | 0.148 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.121 | Idelalisib | — uncovered |
| HYPOXIA | 0.119 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.036 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.028 | Inavolisib | — uncovered |